SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Exterior of Novo Nordisk's location in Mainz, Germany
Drug Development
Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss
Novo Nordisk on Wednesday announced it is stopping a late-stage study after its candidate ocedurenone, which the pharma acquired last year in a potential $1.3 billion deal with KBP Biosicences, failed to meet the primary endpoint.
June 27, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Old Russian vintage weight scales
Drug Development
Zealand to Raise $1B in Public Offering to Fund Obesity Candidates
Zealand Pharma is looking to build on last week’s positive Phase Ib trial results by raising around $1 billion in a public offering, with the proceeds being used to advance its obesity candidates.
June 26, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Biopharma items with cyber accents
Policy
Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs
As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.
June 25, 2024
 · 
6 min read
 · 
Tyler Patchen
Pictured: Sarepta sign on a brick building/courtes
FDA
After Full Approval, Sarepta Lays Out Its Next Moves
After winning expanded approval for its gene therapy for Duchenne muscular dystrophy, Sarepta’s leadership and analysts see a sizeable commercial opportunity on the horizon.
June 25, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: J&J's office in Madrid, Spain
Drug Development
J&J’s Blockbuster Tremfya Flops in Phase II Giant Cell Arteritis Trial
Following success in several indications including ulcerative colitis, J&J’s blockbuster drug Tremfya failed to meet a mid-stage study’s primary endpoint in treating giant cell arteritis.
June 25, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A digital mammogram of the breast to dia
Drug Development
G1 Therapeutics Fails Late-Stage Breast Cancer Trial, Plans ‘Targeted’ Headcount Reductions
G1 Therapeutics on Monday reported Phase III study results showing its drug Cosela did not demonstrate a statistically significant effect in overall survival in triple-negative breast cancer patients.
June 24, 2024
 · 
2 min read
 · 
Tyler Patchen
Sarepta and vials/Taylor Tieden for BioSpace
FDA
Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy
On the heels of a Phase III flop for Pfizer’s Duchenne muscular dystrophy gene therapy candidate, the FDA has green lighted the expanded use of Sarepta Therapeutics’ Elevidys.
June 20, 2024
 · 
6 min read
 · 
Tyler Patchen
Pictured: 3D rendering of nerve cells and neurological disease
Drug Development
PTC Reports Positive Phase II Huntington’s Data, FDA Lifts Partial Clinical Hold
PTC Therapeutics said Thursday the FDA has lifted a partial clinical hold on its Huntington’s disease candidate PTC518 after displaying favorable clinical trends in a mid-stage study.
June 20, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Exterior of Roche's facility in Boulogne-Billancourt, France
Business
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies
Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.
June 18, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: The front entrance to the FDA headquarters/iStock, Grandbrothers
FDA
AstraZeneca’s Imfinzi Gets FDA Approval for Treating Endometrial Cancer
AstraZeneca on Monday secured FDA approval for its blockbuster Imfinzi, in combination with chemotherapy, to treat adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
June 17, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A sign on a J.P. Morgan building in Hong Kong/iStock, danielvfung
J.P. Morgan Raises Over $500M for First Biotech Venture Capital Fund
J.P. Morgan’s life sciences venture capital arm on Thursday announced it closed its first biotech fund, targeting companies in cardiometabolic disease, immunology, oncology and genetic medicine.
June 14, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Injection pens for GLP-1 medications in a box and a measuring tape
Drug Development
GLP-1 Global Obesity Market to Reach $111B by 2033, Despite Headwinds: GlobalData
While GLP-1 drugs remain wildly popular and are a highly lucrative sector, data analytics firm GlobalData contends manufacturing and cost will remain overhangs on the obesity market.
June 14, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: 3d illustration of antibodies attacking
Business
Santa Ana Bio Launches With $168M, Targets Autoimmune and Inflammatory Diseases
With Versant Ventures as a founding investor, Santa Ana Bio emerged from stealth Thursday with $168 million in combined Series A and B funding to support plans to have two programs in the clinic by next year.
June 13, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pfizer's signage outside its office in Canada/iStock, JHVEPhoto
Business
Pfizer, Flagship Pioneering to Target Obesity Treatments Under 2023 Partnership
Building on last year’s potential $7 billion partnership with Flagship Pioneering, Pfizer and Flagship-founded ProFound Therapeutics will work on discovering new obesity candidates.
June 12, 2024
 · 
2 min read
 · 
Tyler Patchen
Biogen’s headquarters in Massachusetts
Business
Biogen’s HI-Bio Buy Is Latest Biopharma Spending Spree in Projected $257B Immunology Market
Biogen recently bolstered its pipeline with a potential $1.8 billion acquisition of Human Immunology Biosciences, following other big players looking to cash in on a global immunology market estimated to grow to $257 billion by 2032.
June 12, 2024
 · 
4 min read
 · 
Tyler Patchen
Load More